We scan new podcasts and send you the top 5 insights daily.
In Bruin CLL-322, relapsed patients receiving standard venetoclax-rituximab had a median progression-free survival of roughly 39 months, significantly shorter than the 54 months observed in the Murano trial. Because patients spend 24 months on therapy, 15 months off treatment may limit future venetoclax retreatment durability.
Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.
Clinical data suggests that using time-limited venetoclax-BTK inhibitor combinations in the frontline setting mitigates the emergence of BCL2 or BTK resistance mutations. This provides a key biological rationale supporting this approach, as it preserves future treatment options and allows for successful retreatment.
When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.
In CLL patients with significant nodal bulk, BTK inhibitors are preferred over venetoclax-obinutuzumab. Data shows large disease bulk is a significant independent predictor of shorter progression-free survival with the venetoclax doublet (Hazard Ratio ~1.8), likely due to stromal support signals in bulky nodes.
In CLL, Progression-Free Survival (PFS) is a misleading metric for clinical benefit. Time-To-Next-Treatment (TTNT) is often much longer because patients can have biochemical or radiological progression by IWCLL criteria but remain asymptomatic and clinically well, delaying the need for a new therapy.
Data from the BRUIN CLL-322 trial shows that adding pirtobrutinib to venetoclax-rituximab (PVR) significantly improves progression-free survival for CLL patients who have previously been treated with a BTK inhibitor. This establishes the triplet as a new, potent, and likely future standard regimen for this high-need population.
Abstract data from the BRUIN CLL-322 trial reveals that adding pirtobrutinib to a venetoclax-rituximab backbone provides a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with previously treated CLL, without a substantial increase in toxicity.
New oral BTK degraders show impressive response rates of 60-80% in CLL patients who have failed both covalent and non-covalent BTK inhibitors. However, the critical unknown is the durability of these responses. Future long-term data will determine their ultimate place in the treatment landscape.
Unlike continuous BTK inhibitor therapy, using a BTK inhibitor as part of a time-limited combination regimen does not appear to select for resistance mutations. This crucial distinction means that a BTK inhibitor could potentially be used again effectively as a subsequent line of therapy if the patient relapses.
In relapsed CLL, venetoclax-rituximab yields a median progression-free survival of under 40 months following covalent BTK inhibitor failure, compared to 54 months in historical chemoimmunotherapy trials. Intensifying therapy with a pirtobrutinib triplet (PVR) cuts progression risk by nearly half in this aggressive post-covalent BTKI population.